SFZN Stock Analysis: Siegfried Holding | SW
Drug Manufacturers - Specialty & Generic | SW, Switzerland | Market Cap: 3.205m CHF | 12M Return: -6.7% | CH0014284498 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 8.14M
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Siegfried Holding AG (SFZN) is a Swiss-based contract development and manufacturing organization (CDMO) that produces active pharmaceutical ingredients (APIs) and finished dosage forms for pharmaceutical clients worldwide. The company operates through two main segments: drug substances, which includes custom API manufacturing and a portfolio of non-exclusive APIs focused on therapeutic areas such as anesthetics, pain and addiction treatment, central nervous system and respiratory diseases, plus pharmaceutical-grade caffeine; and drug products, covering sterile fill-and-finish (vials, ampoules, cartridges, pre-filled syringes), ophthalmics, inhalation capsules, oral solid dosage forms (tablets and capsules), and viral vectors for cell and gene therapies. Founded in 1873 and headquartered in Zofingen, Switzerland, Siegfried offers a broad technology platform spanning chemistry, analytical services, formulation, containment, and cell and gene therapy capabilities.
Within the pharmaceutical CDMO sector, Siegfried serves as an outsourced manufacturing partner to both brand-name drug developers and generic drug producers, allowing clients to access specialized production capacity, regulatory expertise, and technical capabilities without building them in-house. The CDMO model typically involves long-term supply agreements and high regulatory barriers to entry, given the stringent good manufacturing practice (GMP) standards required by health authorities.
- Steriles fill-finish demand expands order pipeline and capacity utilization
- Cell and gene therapy capacity buildout adds high-margin growth vector
- API margin compression persists amid Asian generic competition
| Net Income: 171.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA 0.47 > 1.0 |
| NWC/Revenue: 64.57% < 20% (prev 47.78%; Δ 16.79% < -1%) |
| CFO/TA 0.07 > 3% & CFO 165.8m > Net Income 171.3m |
| Net Debt (820.0m) to EBITDA (313.2m): 2.62 < 3 |
| Current Ratio: 3.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (43.9m) vs 12m ago 2.02% < -2% |
| Gross Margin: 26.97% > 18% (prev 25.69%; Δ 1.27% > 0.5%) |
| Asset Turnover: 61.12% > 50% (prev 65.64%; Δ -4.51% > 0%) |
| Interest Coverage Ratio: 19.38 > 6 (EBIT TTM 210.9m / Interest Expense TTM 10.9m) |
| A: 0.36 (Total Current Assets 1.22b - Total Current Liabilities 353.1m) / Total Assets 2.42b |
| B: 0.44 (Retained Earnings 1.06b / Total Assets 2.42b) |
| C: 0.10 (EBIT TTM 210.9m / Avg Total Assets 2.19b) |
| D: 0.70 (Book Value of Equity 994.7m / Total Liabilities 1.42b) |
| Altman-Z'' = 5.16 = AAA |
| DSRI: 1.00 (Receivables 328.0m/317.0m, Revenue 1.34b/1.29b) |
| GMI: 0.95 (GM 25.69% / 26.97%) |
| AQI: 1.05 (AQ_t 0.05 / AQ_t-1 0.04) |
| SGI: 1.04 (Revenue 1.34b / 1.29b) |
| TATA: 0.00 (NI 171.3m - CFO 165.8m) / TA 2.42b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of September 27, 2026, the stock is trading at CHF 72.60 with a total of 119,222 shares traded. Over the past week, the price has changed by -0.75%, over one month by -2.48%, over three months by +0.62% and over the past year by -6.69%.
Current recommended Stop Loss: 68.90 (which is 5.1% or 1.9 ATR below the current price).
Siegfried Holding has no consensus analysts rating.
P/E Trailing = 18.7564
P/E Forward = 14.8368
P/S = 2.3892
P/B = 3.268
P/EG = 1.3869
Revenue TTM = 1.34b CHF
EBIT TTM = 210.9m CHF
EBITDA TTM = 313.2m CHF
Long Term Debt = 375.2m CHF (from longTermDebt, last fiscal year)
Short Term Debt = 200.0m CHF (from shortTermDebt, last fiscal year)
Debt = 925.2m CHF (from shortLongTermDebtTotal, last quarter)
Net Debt = 820.0m CHF (calculated: Debt 925.2m - CCE 105.2m)
Enterprise Value = 4.02b CHF (3.20b + Debt 925.2m - CCE 105.2m)
Interest Coverage Ratio = 19.38 (Ebit TTM 210.9m / Interest Expense TTM 10.9m)
EV/FCF = -220.6x (Enterprise Value 4.02b / FCF TTM -18.2m)
FCF Yield = -0.45% (FCF TTM -18.2m / Enterprise Value 4.02b)
FCF Margin = -1.36% (FCF TTM -18.2m / Revenue TTM 1.34b)
Net Margin = 12.77% (Net Income TTM 171.3m / Revenue TTM 1.34b)
Gross Margin = 26.97% ((Revenue TTM 1.34b - Cost of Revenue TTM 979.6m) / Revenue TTM)
Gross Margin QoQ = 26.97% (prev 26.97%)
Tobins Q-Ratio = 1.67 (Enterprise Value 4.02b / Total Assets 2.42b)
Interest Expense / Debt = 1.18% (Interest Expense 10.9m / Debt 925.2m)
Taxrate = 19.29% (40.9m / 211.8m)
NOPAT = 170.2m (EBIT 210.9m * (1 - 19.29%))
Current Ratio = 3.45 (Total Current Assets 1.22b / Total Current Liabilities 353.1m)
Debt / Equity = 0.93 (Debt 925.2m / totalStockholderEquity, last quarter 994.7m)
Debt / EBITDA = 2.62 (Net Debt 820.0m / EBITDA 313.2m)
Debt / FCF = -44.96 (negative FCF - burning cash) (Net Debt 820.0m / FCF TTM -18.2m)
Total Stockholder Equity = 1.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.81% (Net Income 171.3m / Total Assets 2.42b)
RoE = 16.61% (Net Income TTM 171.3m / Total Stockholder Equity 1.03b)
RoCE = 14.99% (EBIT 210.9m / Capital Employed (Equity 1.03b + L.T.Debt 375.2m))
RoIC = 7.75% (NOPAT 170.2m / Invested Capital 2.20b)
WACC = 6.30% (E(3.20b)/V(4.13b) * Re(7.84%) + D(925.2m)/V(4.13b) * Rd(1.18%) * (1-Tc(0.19)))
Discount Rate = 7.84% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 7.92 | Cagr: 0.47%
[DCF] Fair Price = unknown (Cash Flow -18.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 95.96 | Revenue CAGR: 2.12% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=4.15 | Chg30d=+1.18% | Revisions=+0% | GrowthEPS=+12.5% | GrowthRev=+7.1%
EPS next Year (2027-12-31): EPS=4.72 | Chg30d=-0.29% | Revisions=+0% | GrowthEPS=+13.7% | GrowthRev=+9.7%
[Analyst] Revisions Ratio: +0% (up=6, down=6)